Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
Saved in:
Main Authors: | John K. Chan (Author), David S. Lakomy (Author), Yassmina McDonald (Author), Daniel S Kapp (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2020-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with ESR1 gene amplification
by: Jenny L. Soiffer, et al.
Published: (2024) -
Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
by: Kaito Mimura, et al.
Published: (2022) -
A complete durable response of vaginal clear cell carcinoma with pembrolizumab: A case report
by: Hector S. Porragas-Paseiro, et al.
Published: (2023) -
Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
by: Varun Khetan, et al.
Published: (2021) -
Pattern of disease and response to pembrolizumab in recurrent cervical cancer
by: Kathryn M. Miller, et al.
Published: (2021)